Nano-X Imaging Ltd. (NASDAQ: NNOX), a company focused on transforming preventive healthcare through an integrated medical imaging and services platform, has announced a securities purchase agreement with a single long-term institutional investor for a registered direct offering. The offering is expected to generate approximately $8 million in gross proceeds before fees and expenses, according to a press release published by InvestorWire.
The financing involves the sale of 8 million ordinary shares, or prefunded warrants in lieu thereof, along with warrants to purchase up to an additional 8 million ordinary shares, at a combined purchase price of $1.00 per share and accompanying warrant. The warrants will have an exercise price of $1.15 per share, become exercisable six months after issuance, and expire five years after the closing. The offering is anticipated to close on or about Aug. 7, 2026, subject to customary closing conditions. Nano-X stated that it intends to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction.
This capital raise comes at a time when Nano-X is advancing its mission to expand the reach of medical imaging beyond traditional hospital settings. The company’s ecosystem includes the Nanox.ARC, a 3D multi-source digital tomosynthesis system designed for cost-effectiveness and scalability; Nanox.AI, a suite of algorithms that augment CT imaging interpretation to identify early signs of chronic disease; Nanox.CLOUD, a secure cloud-based platform for data management and imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts; and Nanox Health IT, offering RIS, PACS, AI, and secure infrastructure solutions. By integrating these components, Nano-X aims to lower barriers to adoption, improve utilization, and advance preventive care worldwide.
The significance of this offering lies in its potential to accelerate Nano-X's strategic initiatives. With fresh capital, the company can continue to develop its proprietary digital X-ray technology and AI-driven analytics, which are central to its vision of early disease detection and improved patient outcomes. The participation of a long-term institutional investor suggests confidence in Nano-X's long-term prospects, despite the dilutive effect of the offering. For investors, this move underscores the company's commitment to funding its growth while navigating the capital-intensive medical device and healthcare technology sectors.
Nano-X's focus on preventive health is particularly relevant as healthcare systems worldwide shift toward early intervention and cost-efficient diagnostic solutions. The company’s integrated platform addresses key bottlenecks in imaging, such as high equipment costs and limited access in underserved regions. By securing additional funding, Nano-X is better positioned to scale its operations, expand its marketplace, and forge partnerships that could enhance its competitive edge.
As the offering progresses, market observers will watch how Nano-X allocates the proceeds and whether it can translate its technological innovations into commercial success. The company’s ability to execute on its roadmap will be crucial in determining its impact on the medical imaging landscape. For now, the registered direct offering provides a financial cushion to support ongoing research, regulatory efforts, and market expansion.
